Respirometry on permeabilized cells: is the new compound an uncoupler?
An investigator measures oxygen consumption in digitonin-permeabilized HEK293 cells at 37 °C with pyruvate plus malate as substrates. Rates are expressed as pmol O₂·s⁻¹ per 10⁶ cells and are means of triplicate wells. Sequential additions to the control plate give: basal 24; after ADP 40; after oligomycin 8; after FCCP 56; after rotenone plus antimycin A 4. A parallel plate is run with 1 µM of a new compound, X-17, added before the ADP step: basal 15, after ADP 25, after oligomycin 10, after FCCP 28, after rotenone plus antimycin A 4. Cell number, protein content and starting viability are matched between plates. The reviewer asks two things: whether X-17 is an uncoupler, and whether the control preparation is intact enough for any conclusion to mean anything. Total run time is 45 minutes, and the control plate's basal rate drifts down by 8% between the first and last measurement.
1. Calculate the respiratory control ratio, ATP-linked rate, proton-leak rate and spare respiratory capacity for the control plate, and judge whether the preparation is intact.
Read the worked answer
Subtract the rotenone/antimycin-A rate of 4 first, since it is non-mitochondrial oxygen consumption and inflates every ratio: corrected basal 20, ADP 36, oligomycin 4, FCCP 52.
- RCR = ADP state ÷ oligomycin state = 36 ÷ 4 = 9.
- ATP-linked = basal − oligomycin = 20 − 4 = 16 (80% of basal).
- Proton leak = 4 (20% of basal).
- Spare capacity = (FCCP − ADP) ÷ FCCP = (52 − 36) ÷ 52 = 31%.
All four fall in the range expected for an intact, coupled preparation: RCR well above 4, leak below 25% of basal, spare capacity above 20%. A leak fraction above roughly half of basal would suggest membrane damage or poor permeabilization, and a low RCR would mean the cells were already partly uncoupled before any drug was added.
The 8% downward drift is a caveat, not a disqualifier: it is small, in one direction, and applies equally to both plates. It does mean the FCCP value, taken last, may be slightly underestimated, so the spare-capacity figure is conservative. The key point is that any comparison with X-17 must be made on corrected values, because the small absolute rate of 4 is a large fraction of the X-17 oligomycin rate of 10 (corrected 6).
2. Is X-17 an uncoupler? Classify it, and name the two experiments that would most efficiently separate your remaining hypotheses.
Read the worked answer
An uncoupler (FCCP, DNP) collapses the proton gradient. Oxygen consumption rises because the respiratory chain works flat out to restore it, mitochondrial ATP output falls, basal respiration approaches the FCCP maximum, and oligomycin becomes irrelevant. X-17 does the opposite on the decisive measurement: basal falls from 24 to 15, and the FCCP-stimulated rate collapses from 56 to 28.
That last number is the crux. FCCP has already uncoupled the membrane, so the rate measured after FCCP reflects the maximum the electron transport chain and substrate supply can deliver. An uncoupler cannot lower that ceiling. A compound that halves it is limiting electron supply or chain capacity - a complex-I or dehydrogenase effect, impaired pyruvate uptake, or downstream chain inhibition.
The secondary signal is genuinely ambiguous. The oligomycin-insensitive fraction rises from 20% to 67% of basal (10 of 15), which is consistent with partial uncoupling but equally with cells that are losing membrane integrity, so the proton gradient leaks through a damaged bilayer. The two effects might even be one target seen at different potencies.
Two experiments settle it. First, bypass complex I: add succinate plus rotenone. If the FCCP maximum recovers toward 56, X-17 acts on complex I or pyruvate metabolism; if it stays at 28, the lesion is downstream. Second, check integrity directly - trypan blue or LDH release after X-17, plus measured lactate output. If cells are dying, every respirometry value in that plate is uninterpretable.
3. The team now wants to compare cells overexpressing a glycolytic enzyme with vector controls and plans to normalize respiration to cell number. What is the pitfall and how should they normalize?
Read the worked answer
Normalizing to cell number assumes one cell equals one unit of mitochondrial capacity. That assumption breaks exactly here. Cells engineered to overexpress a metabolic enzyme often change size, growth rate, cell-cycle distribution and mitochondrial content, and a respirometer counting cells cannot tell a larger cell from a cell with more mitochondria. A 30% increase in oxygen consumption per cell could be nothing but a 30% increase in cell volume, or a shift from oxidative to glycolytic metabolism could reduce respiration per cell even while mitochondrial mass is unchanged.
Better denominators, in order of preference. Citrate synthase activity is the standard index of mitochondrial mass; it is not part of the respiratory chain, so it is not affected by the manipulation, and it corrects for changes in mitochondrial biogenesis. Total protein is convenient but is confounded when the overexpressed protein is itself abundant. mtDNA copy number and cardiolipin content are alternatives, and transmission electron microscopy volume density is the gold standard if the question is truly about mitochondrial content.
The practical answer is to report both raw per-cell rates and at least one mass-corrected ratio, and to state which conclusion depends on which denominator. If the per-cell effect disappears after citrate synthase correction, the honest conclusion is that the enzyme changed cell size or mitochondrial content, not respiratory efficiency. It is also worth measuring extracellular acidification or lactate in parallel, because a shift between oxidative and glycolytic ATP supply can move respiration in either direction without any change in the machinery itself.